Boehringer Ingelheim opens $800M biopharma plant in Vienna

Boehringer Ingelheim's new large-scale cell culture manufacturing plant in Vienna, Austria, became operational in October 2021. The project cost over $800 million, adds 185,000 liters of production capacity and 500 new jobs, and includes 48 stainless steel bioreactors.

“Last week, the site became operational.”endpoints.news

• 1 source
• endpoints.newsSix years and nearly $1B later, Boehringer Ingelheim’s largest ever investment is now operationalJosh SullivanOct 14, 2021

Summarized from public sources; check the original articles before acting on it.